Esperion Therapeutics, Inc. (ESPR) EPS Estimated At $-1.80

February 23, 2018 - By Michael Collier

 Esperion Therapeutics, Inc. (ESPR) EPS Estimated At $ 1.80
Investors sentiment increased to 1.67 in Q3 2017. Its up 0.45, from 1.22 in 2017Q2. It improved, as 11 investors sold Esperion Therapeutics, Inc. shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported.
Pictet Asset Management has invested 0.04% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Us Bank & Trust De invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Great West Life Assurance Can has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Moreover, Pinnacle Ltd has 0.66% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 717,813 shares. Balyasny Asset Mgmt Ltd Company reported 393,150 shares. 783,059 are owned by Discovery Ltd Limited Liability Company Ct. State Of New Jersey Common Pension Fund D stated it has 36,875 shares. Credit Suisse Ag reported 1.06M shares. Cim Inv Mangement Incorporated holds 0.08% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 4,381 shares. State Common Retirement Fund has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Renaissance Technologies Ltd Company holds 14,500 shares or 0% of its portfolio. Voya Investment Mgmt Limited Com holds 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 7,673 shares. J Goldman And L P owns 30,020 shares. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 794 shares. St Johns Invest Mgmt Co Limited Com has invested 0.01% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Analysts expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report $-1.80 EPS on February, 28.They anticipate $0.51 EPS change or 39.53 % from last quarter’s $-1.29 EPS. After having $-1.86 EPS previously, Esperion Therapeutics, Inc.’s analysts see -3.23 % EPS growth. The stock increased 2.78% or $2.11 during the last trading session, reaching $77.94. About 499,150 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since February 23, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 10 have Buy rating, 0 Sell and 8 Hold. Therefore 56% are positive. Esperion Therapeutics had 56 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Buy” rating by Citigroup on Wednesday, June 29. On Tuesday, October 3 the stock rating was maintained by Northland Capital with “Buy”. On Friday, November 6 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Underperform” rating by Credit Suisse on Wednesday, June 29. Citigroup downgraded the shares of ESPR in report on Monday, November 14 to “Neutral” rating. The stock has “Buy” rating by Jefferies on Wednesday, August 9. The company was maintained on Wednesday, June 29 by Lake Street. Chardan Capital Markets maintained the shares of ESPR in report on Monday, August 31 with “Sell” rating. Deutsche Bank maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Wednesday, August 9. Deutsche Bank has “Buy” rating and $64 target. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Overweight” rating by Barclays Capital on Wednesday, February 24.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $2.07 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.